Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021 ↗
The biotech's shares have definitely lost their shine in 2021. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin ↗
These unloved cancer stocks should dramatically outperform Dogecoin over the long haul. 
Via The Motley Fool
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:... 
Via Benzinga
Topics Stocks
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 ↗
Upgrades For Delek US Holdings Inc (NYSE:DK), Tudor Pickering upgraded the previous rating of Hold to Buy. For the first quarter, Delek US Hldgs had an EPS of $1.69,... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban... 
Via Benzinga
News headline image
Why Adaptimmune Therapeutics Crushed the Market Today ↗
A key pipeline drug performs well in a mid-stage clinical trial. 
Via The Motley Fool
News headline image
38 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03. Precipio, Inc. (NASDAQ: PRPO) gained 22.3% to $5.05. Precipio recently announced it launched a new, four-... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
News headline image
20 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers PDS Biotechnology Corporation (NASDAQ: PDSB) rose 18% to $6.77 in pre-market trading as traders circulated abstract from American Society Of Clinical Oncology website.... 
Via Benzinga
News headline image
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel... 
Via Benzinga
News headline image
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-... 
Via Benzinga
News headline image
Earnings Outlook for Adaptimmune Therapeutics ↗
On Thursday, May 06, Adaptimmune Therapeutics (NASDAQ:ADAP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.